Ryan Gentzler, MD· @ryangentzler · X·· 14 hours agoScore70
Body
Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.”
Many patients never receive 2nd line.
#ESMO26
43 views · 0 likes · 0 reposts · 1 reply
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgReplies in this thread
- Ryan Gentzler, MD@ryangentzler
Another memorable quote from this talk: “these data deliver real hope where hope has been in short supply”
Source: Ryan Gentzler, MD · x.com